Kathy L. Hibbs - Jan 5, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Director
Signature
/s/ Agnieszka Gallagher, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
Jan 5, 2024
Transactions value $
$0
Form type
4
Date filed
1/9/2024, 06:05 PM
Previous filing
Dec 29, 2023
Next filing
Jan 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +79.4K $0.00 79.4K Jan 5, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to buy) Award +206K 206K Jan 5, 2024 Common Stock 206K $2.47 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2 25% of the shares underlying the option vest on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is fully vested, subject to the Reporting Person's continued service through the applicable vesting date.
F3 Pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic, Inc. ("Soma Logic") (the "Merger"), each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 (the "Exchange Ratio") rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent.
F4 Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time.